Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Operating Income: 2019-2025

Historic Operating Income for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$145.2 million.

  • BridgeBio Pharma's Operating Income rose 24.28% to -$145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$609.9 million, marking a year-over-year decrease of 12.04%. This contributed to the annual value of -$593.0 million for FY2024, which is 2.37% up from last year.
  • BridgeBio Pharma's Operating Income amounted to -$145.2 million in Q3 2025, which was down 8.13% from -$134.3 million recorded in Q2 2025.
  • BridgeBio Pharma's Operating Income's 5-year high stood at $343,000 during Q1 2024, with a 5-year trough of -$226.0 million in Q4 2024.
  • For the 3-year period, BridgeBio Pharma's Operating Income averaged around -$144.0 million, with its median value being -$146.1 million (2023).
  • Its Operating Income has fluctuated over the past 5 years, first soared by 100.27% in 2024, then tumbled by 30,529.15% in 2025.
  • BridgeBio Pharma's Operating Income (Quarterly) stood at -$165.6 million in 2021, then climbed by 21.97% to -$129.2 million in 2022, then plummeted by 37.28% to -$177.4 million in 2023, then declined by 27.40% to -$226.0 million in 2024, then grew by 24.28% to -$145.2 million in 2025.
  • Its Operating Income stands at -$145.2 million for Q3 2025, versus -$134.3 million for Q2 2025 and -$104.4 million for Q1 2025.